NCT04312009
Losartan for Patients With COVID-19 Requiring Hospitalization
See it on ClinicalTrials.gov ↗205 people
40%
60%
82 womenmiddle line = equal numbers123 men
- Phase
- PHASE2
- Paid for by
- University of Minnesota
- Finished
- 2021-02-01
- Health conditions
- Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection
- Who could join
- Anyone
- Ages
- 18 Years – no maximum
- Average age
- Not reported
- Age 65+
- 22.9%
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- White 40% · Black / African American 32.7% · Not reported 22.4% · Asian 4.4% · Native Hawaiian / Pacific Islander 0.5% · American Indian / Alaska Native 0% · More than one race 0%
Women left out
- No pregnant women
Women who were pregnant could not join.
“Pregnant or breastfeeding”
- No breastfeeding moms
Women who were breastfeeding could not join.
“Pregnant or breastfeeding”
- No hormonal birth control
Women on the pill, patch, ring, shot, implant or hormonal IUD could not join.
“…ocol allowed version of contraception: intrauterine device, Depo-formulation of hormonal contraception (e.g. medroxyprogesterone acetate / Depo-Provera), subcutaneous contraceptive (e.g. Nexplanon), daily oral contraceptives with verbalized…”
- No kidney or liver problems
Women with kidney or liver problems were turned away.
“Patient reported history or electronic medical record history of kidney disease, defined as:”
Study titles and rules are shown in their original English.